Matches in Nanopublications for { ?s ?p "DDI between golimumab and Tofacitinib - Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB06674_DB08895 title "DDI between golimumab and Tofacitinib - Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy." assertion.